​IMV is Aiming to Take Immunotherapy to the Next Level

Spotlight Companies | |

Here's how IMV is shifting the paradigm in immunotherapy.

​Why IMV Wants You to Rethink What You Know About Immunotherapy — Q&A with CEO Frederic Ors

Spotlight Companies | |

What sets IMV's technology apart is that it essentially aims to re-engineer immune system responses to deliver a desired effect, creating a new mechanism of action.

​How Immunovaccine is Leading a New Frontier in the Fight Against Cancer

Spotlight Companies | |

The company's revolutionary DepoVax™ platform makes it a key player in the future of cancer treatments.

​Why Immunovaccine Ranks Among Top 10 Best Performing OTCQX Companies

Spotlight Companies | |

Here's what's behind the company's impressive streak.

​Immunovaccine’s DepoVax™ Continues to Play a Pivotal Role in the Future of Modern Medicine

Spotlight Companies | |

With its innovative DepoVax™ platform, Immunovaccine is quickly emerging as a leading name in the immunotherapy and cancer vaccine space of the life sciences sector.

​Madrigal: Best in Class in NASH?

MoneyShow | |

NASH is a tremendous opportunity for biotech/drug developers as the potential market could be in the tens of billions.

MetaStat (MTST): Targeting Pathways of Cancer Metastasis

Edward Kim | |

MetaStat is developing therapies that target the pathways of tumor cell invasion and metastasis.

​Immunovaccine’s Ovarian Cancer Study Shows Promising Data

Spotlight Companies | |

The company says its found evidence of “the holy grail of combination immunotherapy.”

What's Done Better for Investors: Small Biotechs or Big Pharma?

The Life Sciences Report | |

When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies

Investment Opportunities in Emerging Therapeutic Industries

The Life Sciences Report | |

Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of

Sponsored Financial Content

Market Movers